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Background/aim: To retrospectively reevaluate brain fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging
studies with 3-dimensional stereotactic surface projection (NEUROSTAT) software in order to detect changes in regional brain
metabolism and to find out its contribution to the final diagnosis.
Materials and methods: A total of 48 cases were included in this study. According to clinical evaluation and neuropsychometric test
results, there were 17 (35%) patients with probable Alzheimer disease (AD), 17 (35%) patients with probable frontotemporal dementia
(FTD), and 14 (30%) patients with undefined advanced dementia. Brain FDG-PET imaging studies were interpreted visually and also
using 3-dimensional stereotactic surface projection.
Results: Clinic and PET findings were consistent in 20 patients and inconsistent in 14 patients. When consensus diagnosis was taken
as the reference, the sensitivity, specificity, accuracy, and positive and negative predictive values of FDG-PET imaging were 93%, 85%,
90%, 90%, and 89% respectively, for AD diagnosis. The same values were 85%, 93%, 90%, 89%, and 90%, respectively, for FTD definition.
Conclusion: Using automatized programs that enable quantitative evaluation of regional brain glucose metabolism, in addition to visual
evaluation, may increase diagnostic efficiency, as well as minimize interobserver and/or intercenter variability.
Key words: Alzheimer disease, frontotemporal dementia, fluor-18-FDG-PET, brain positron emission tomography

1. Introduction
Diagnosing and differentiating dementia is becoming
increasingly important, as there are several new diseasespecific and effective treatment options. However, the only
way to definitively diagnose dementia is with a postmortem
histopathological examination. Therefore, patients are
currently diagnosed with a “probable cause” of dementia
and treated for symptoms based on clinical history,
progress and variation of symptoms, laboratory tests,
brain scans, and neuropsychological assessments. These
diagnostic tests are highly accurate in advanced dementia
cases, but even in the most experienced clinics, patients
in the early stages of dementia may be misdiagnosed if
the symptomatology of the disease is not yet present (1).
Therefore, there is a need for a technique that can be used
to determine a reliable diagnosis of dementia that can also
identify the pathognomonic changes of the early stages of
disease.
* Correspondence: metin.halac@yahoo.com

Fluor-18-fluorodeoxyglucose
positron
emission
tomography (FDG-PET) can detect glucose consumption
in vivo. This technique can be used to determine the
difference in glucose metabolism in the early phases of
pathophysiological processes, before these differences
cause morphological changes. FDG-PET can detect
areas with reduced glucose consumption, including
neurodegeneration and gliosis in the central nervous
system. Therefore, this method can also be used to
diagnose other neuropsychiatric processes (2).
Many studies have shown that FDG-PET imaging can
detect different topographical distributions of regional
brain glucose metabolism and therefore can aid in the
various diagnoses of dementia, including Alzheimer
disease (AD), frontotemporal dementia (FTD), vascular
dementia (VD), and dementia with Lewy bodies (DLB)
(3,4). In cases of AD, a pattern of hypometabolism is
typically observed in the parietotemporal cortex and
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in the posterior cingulate cortex regions. In addition to
those regions affected in AD cases, areas of the visual
cortexes are also affected in DLB cases. However, in cases
of FTD, lower FDG uptake is first observed in the frontal
lobes and in the anterior temporal regions. In VD cases,
multiple focal hypometabolic areas are generally observed,
which indicates a random distribution in the cerebral
cortex. Many researchers have shown that the diagnostic
sensitivity of hypometabolism in the temporoparietal
cortical areas varies; it is approximately 90% for patients
with AD (5–7). On the other hand, some researchers
have shown that the diagnostic accuracy of FDG-PET
is lower than 90%, especially in the early stages of the
disease (8–10). The diagnostic accuracy of FDG-PET can
be increased if the images are evaluated by an experienced
physician and/or if the images are evaluated with software
capable of conducting quantitative statistical analyses,
such as 3-dimensional stereotactic surface projection
(3D-SSP) and statistical parametric mapping (SPM). These
programs can be used to increase the diagnostic accuracy
of FDG-PET by decreasing the number of false positive or
false negative results in the early stages of the disease, or in
cases with atypical clinical presentations (11,12).
The aim of this study was to determine the importance
of FDG-PET imaging for the diagnosis of dementia
in patients with an early diagnosis of dementia in
accordance with the National Institute of Neurologic and
Communicative Disorders and Stroke (NINCDS) and
Alzheimer’s Disease and Related Disorders Association
(ADRDA) criteria. All PET images were reevaluated
retrospectively with 3D-SSP NEUROSTAT software
to compare changes in regional brain metabolism. In
addition, data derived from neuropsychological tests were
also taken into consideration.

2. Materials and methods
2.1. Patients
After obtaining approval from the ethics committee, this study
included 48 patients who underwent neuropsychometric
tests and brain FDG-PET imaging between December 2005
and April 2011. The data were examined retrospectively with
the aim of obtaining the differential diagnosis of dementia.
All of the patients had a probable diagnosis of dementia
based on criteria developed by NINCDS-ADRDA and/or
frontotemporal lobar degeneration. The mean age of the
patients was 61.48 ± 8.60 years (range: 29–81 years), and 14
of the patients (29%) were male and 34 were female (71%).
Table 1 summarizes the mean age, years of education, and
sex distribution of the patients. According to the clinical
findings and neuropsychological test results (CLINIC),
there were 17 (35%) patients with probable AD, 17 (35%)
patients with probable FTD, and 14 (30%) patients with an
undefined advanced dementia (Table 2).
2.2. Neuropsychological tests
The following tests were used to assess neuropsychological
performance: Wechsler Memory Scale (WMS) subtest
II, WMS subtest III, WMS subtest IV, WMS subtest VI,
Wisconsin Card Sorting Test, Stroop Test, Binary Thinking
and Analogies Test Abstraction, Boston Denotation, and
Standardized Mini Mental Test.
2.3. 18F-FDG PET/CT imaging
2.3.1. Image recording and processing
Following an intravenous injection of 259-518 MBq F-18
FDG, attenuation-corrected PET/CT (Siemens Biograph
LSO HI-RES PET-CT, USA) images were acquired. After
iterative reconstruction, 0.3-cm-thick section images from
both CT and PET were obtained in the transaxial, coronal,
and sagittal planes.

Table 1. The demographic characteristics of patients with the probable diagnosis of dementia.
Disease

Age, years

Education, years

Duration of disease, years Female/male ratio (%)

AD

17

59.58 ± 6.91 (51–76)

8.64 ± 3.60 (5–15)

2.35 ± 0.8 (1–4)

13/17 (76)

Early stage

3

69.33 ± 7.02 (62–76)

7 ± 3.46 (5–11)

2.5 ± 0.7 (2–3.5)

1/3

Moderate stage

11

56.90 ± 4.45 (51–68)

9.18 ± 3.25 (5–15)

2.7 ± 0.87 (1–4)

9/11 (81)

Late stage

3

59.66 ± 7.23 (55–68)

8.33 ± 5.77 (5–15)

2.66 ± 0.76 (2–3.5)

3/3

FTD

17

62.29 ± 10.62 (29–80)

8.52 ± 4.09 (5–15)

2.66 ± 1.18 (0.25–5)

12/17 (71)

Early stage

6

65.16 ± 5.63 (59–75)

9.33 ± 4.96 (5–15)

2.75 ± 0.9 (1–4)

3/6

(50)

Moderate stage

8

59.75 ± 14.43 (29–80)

7.25 ± 3.70 (5–11)

2.53 ± 1.52 (0.25–5)

7/8

(87)

Late stage

3

63.33 ± 6.50 (57–70)

10.33 ± 5.03 (5–15)

2.83 ± 0.76 (2–3.5)

2/3 (66)

Undefined group

14

61.4 ± 11.58 (53–81)

5.57 ± 3.22(0–11)

2.57 ± 1.14 (1–4)

9/14 (64)
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Table 2. Demographic and diagnostic characteristics of the patients.
No..

Name

Age/sex

Time (years)

Clinical diagnosis

PET diagnosis

Consensus diagnosis

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

MD
AGK
KÇ
GSA
GA
LÖ
YK
SA
FB
RC
ŞS
EM
AE
MD
ZK
ODU
AD
SE
ÜG
HŞ
AÖ
FÖ
NA
KÇ
NK
MC
VE
VG
AY
ŞK
RŞ
NK
CÇ
GG
İTG
BZ
İA
PK

62/M
70/M
76/F
55/F
57/F
60/F
57/F
54/F
58/F
54/F
58/F
51/F
68/M
54/M
56/F
68/F
55/F
68/F
57/F
81/M
68/M
59/F
53/F
67/F
61/F
65/M
62/M
57/F
72/F
54/F
55/M
59/F
68/M
63/F
62/M
75/F
64/M
54/F

2
2
3.5
1
3
2.5
2
3
4
3
2
2.5
4
3
2.5
3.5
2
4
2.5
2
1
4
4
2.5
3
1
1
2
2
3
4
1
3
3
3
2.5
4
5

AD-EARLY STAGE
AD-EARLY STAGE
AD-EARLY STAGE
AD-MODERATE STAGE
AD-MODERATE STAGE
AD-MODERATE STAGE
AD-MODERATE STAGE
AD-MODERATE STAGE
AD-MODERATE STAGE
AD-MODERATE STAGE
AD-MODERATE STAGE
AD-MODERATE STAGE
AD-MODERATE STAGE
AD-MODERATE STAGE
AD-LATE STAGE
AD-LATE STAGE
AD-LATE STAGE
UNDEFINED
UNDEFINED
UNDEFINED
UNDEFINED
UNDEFINED
UNDEFINED
UNDEFINED
UNDEFINED
UNDEFINED
UNDEFINED
UNDEFINED
UNDEFINED
UNDEFINED
UNDEFINED
FTD-EARLY STAGE
FTD-EARLY STAGE
FTD-EARLY STAGE
FTD-EARLY STAGE
FTD-EARLY STAGE
FTD-EARLY STAGE
FTD-MODERATE STAGE

AD
FTD
FTD
AD
AD
AD
AD
AD
AD
AD
AD
FTD
FTD
FTD
AD
AD
AD
AD
AD
AD
AD
AD
AD
AD
AD
FTD
FTD
FTD
FTD
FTD
FTD
AD
FTD
FTD
FTD
UNDEFINED
FTD
AD

39

NE

60/F

2

FTD-MODERATE STAGE

AD

40

AE

63/F

2.5

FTD-MODERATE STAGE

AD

41

SP

62/F

1

FTD-MODERATE STAGE

AD

42
43
44
45
46
47
48

AG
BZG
GD
YE
HD
HFY
ŞŞ

80/M
65/F
65/F
29/F
57/F
70/M
63/F

3
2.5
4
0.25
3
3.5
2

FTD-MODERATE STAGE
FTD-MODERATE STAGE
FTD-MODERATE STAGE
FTD-MODERATE STAGE
FTD-LATE STAGE
FTD-LATE STAGE
FTD-LATE STAGE

UNDEFINED
UNDEFINED
FTD
FTD
AD
FTD
FTD

AD-EARLY STAGE
AD-EARLY STAGE
FTD-EARLY STAGE
AD-MODERATE STAGE
AD-MODERATE STAGE
AD-MODERATE STAGE
AD-MODERATE STAGE
AD-MODERATE STAGE
AD-MODERATE STAGE
AD-MODERATE STAGE
AD-MODERATE STAGE
FTD-MODERATE STAGE
FTD-EARLY STAGE
AD-MODERATE STAGE
AD-LATE STAGE
AD-LATE STAGE
AD-LATE STAGE
AD-LATE STAGE
AD-LATE STAGE
AD-LATE STAGE
AD-LATE STAGE
AD-LATE STAGE
AD-LATE STAGE
AD-LATE STAGE
AD-LATE STAGE
FTD-LATE STAGE
FTD-LATE STAGE
FTD-LATE STAGE
FTD-LATE STAGE
FTD-LATE STAGE
FTD-LATE STAGE
AD-LATE STAGE
FTD-EARLY STAGE
FTD-EARLY STAGE
FTD-EARLY STAGE
FTD-EARLY STAGE
FTD-EARLY STAGE
AD-MODERATE STAGE
AD-MODERATE STAGE
(FRONTAL VARIANT)
AD-EARLY STAGE
AD-MODERATE STAGE
(FRONTAL VARIANT)
FTD-MODERATE STAGE
FTD-MODERATE STAGE
FTD-MODERATE STAGE
FTD-MODERATE STAGE
AD-LATE STAGE
FTD-LATE STAGE
FTD-LATE STAGE

AD: Alzheimer dementia, FTD: frontotemporal dementia.
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2.3.2. Assessment of FDG-PET images
Based on the symmetry between the hemispheres, the
visual assessment of PET images was performed by
evaluating the changes in FDG uptake in both the cortical
and subcortical areas. Moreover, the nondiagnostic CT
images that were equivalent to the PET sections were
reviewed, and the areas with different FDG uptake were
examined in order to detect structural abnormalities.
In addition to the visual assessment, the axial sectional
images of PET were also evaluated with 3D-SSP software,
also known as NEUROSTAT (13). This program was used
to compare the counts on each and every image unit (voxel)
of the brain images after they were resized and corrected
for rotation. The images were imported into a template
with the Talairach coordinates in a standard format and
were compared with a normal database of matched ages
(age ranges of 19–30, 31–54, and 55–91 years). After
converting the images to a color scale, the regional
deviations (z-score) in the patients were compared to the
brain templates, and the standard deviation values were
recorded in numerical format from 8 different projections
(right lateral, left lateral, superior, inferior, anterior,
posterior, right medial, left medial).
2.4. Consensus diagnosis
A probable diagnosis of dementia was agreed upon for
each patient (consensus) whose clinical findings and PET
images were compatible (Table 4). However, some patients
could not be diagnosed due to discordance between the
clinical findings and the PET scan or due to the lack of
clinical findings (n = 14). A probable diagnosis of dementia
was decided for each patient by reevaluating all clinical
findings, neuropsychological test results, criteria described
in the DSM-IV (NINCDS-ADRDA for AD and/or our
own criteria for frontotemporal lobar degeneration), and
PET findings together with an expert geropsychologist.
2.5. Statistical assessment
Statistical analyses were conducted using SPSS 16.0 for
Windows (SPSS Inc., USA). Numerical data are expressed
as mean ± standard deviation, while nominal data are
expressed as frequency (n, %) when reporting descriptive
statistics. Pearson correlation analysis was used to

evaluate linear correlations between the numerical data.
The regional z-score distributions in AD and FTD cases
were analyzed by histogram graphics. In addition, the
differences in the z-scores derived in accordance with the
4 different regional normalizations in each of the 2 disease
groups were compared with a McNemar test and Pearson
correlation analysis. The differences in the averages of the
cortical z-scores between the disease groups were assessed
by t-test. P < 0.05 was considered statistically significant.
The sensitivity, specificity, accuracy, and negative
and positive predictive values of FDG-PET and clinical
methods were calculated. In doing so, the consensus
diagnosis was considered to be the reference point.
3. Results
According to clinical findings, 17 (35%) patients were
diagnosed with probable AD, 17 (35%) with probable
FTD, and 14 (30%) with an undefined type of advanced
dementia. On the other hand, based on the evaluation of
the PET scans, 26 (54%) patients were classified with AD,
19 (40%) with FTD, and 3 (6%) with an undefined type
(see Table 3). Dementia type was classified based on the
PET scan findings for all of the patients who were unable
to be diagnosed by clinical findings (n = 14). However, 3
patients who were not able to be diagnosed by PET images
were diagnosed with FTD through consensus diagnosis.
Fourteen of the 34 patients had discordant clinical
findings and PET results (9 FTD, 5 AD), while 20 patients
(12 AD, 8 FTD) had compatible clinical findings and
PET scan results (Table 3). Six of the 9 patients who were
clinically diagnosed with FTD were diagnosed with AD by
PET scan evaluation and consensus. Three of the 9 patients
who were diagnosed with undefined dementia by PET
scan were diagnosed with FTD through consensus. Two of
the 5 patients who were clinically diagnosed with AD were
determined to have FTD by PET scan evaluation, while
3 of them were diagnosed with FTD through consensus
(Table 4).
Fourteen patients with clinically undefined advanced
dementia had agreement between their PET scan and
consensus diagnosis. Accordingly, 8 of the 14 patients

Table 3. Consistency table for the clinical and PET diagnoses.
Clinical diagnosis
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PET diagnosis

Alzheimer
dementia

Frontotemporal
dementia

Undefined
dementia

Sum

Alzheimer dementia

12

6

8

26

Frontotemporal dementia

5

8

6

19

Undefined dementia

0

3

0

3

Sum

17

17

14

48
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Table 4. Consistency of consensus diagnosis with clinical and PET diagnoses.
Consensus diagnosis
PET diagnosis

Alzheimer
dementia

Frontotemporal
dementia

Sum

Alzheimer dementia

26 (54%)

0

26

Frontotemporal dementia

2 (4%)

17 (35%)

19

Undefined

0

3 (6%)

3

Alzheimer’s dementia

14 (29%)

3 (6%)

17

Frontotemporal dementia

6 (12.5%)

11 (23%)

17

Undefined

8 (17%)

6 (12.5%)

14

Clinical diagnosis

were diagnosed with AD (Figures 1A and 1B), and 6 of
the patients were diagnosed with FTD (Figures 2A and
2B; Table 4). Consensus diagnosis was compatible with
PET scan results in 43 (90%) of the 48 patients, while the
clinical findings were compatible with consensus diagnosis
in only 25 (52%) patients (Table 4). In 23 of the 28 (82%)
patients with inconsistent results between the PET scan
and clinical findings, consensus results were compatible
with results from the PET scan, and in 5 of 28 (18%)
patients, consensus was compatible with clinical features.
When the 5 patients for whom the consensus diagnosis
was in favor of PET were examined, 2 were considered to
have AD through clinical diagnosis and FTD according
to PET findings, and they were diagnosed with frontal
variant AD through consensus diagnosis. Three patients
with clinically diagnosed FTD and atypical PET findings
were diagnosed with FTD through consensus.

Since there was good consistency (r > 0.85) and no
significant differences between z- score values derived
from the normalizations of different reference cortical
regions (total cerebrum, thalamus, cerebellum, and pons)
by NEUROSTAT analysis, total cerebrum normalization
was considered as a reference point for all related analyses
and assessments (Table 5).
The z-score values derived from parietal, temporal,
frontal, occipital, posterior cingulate, and anterior
cingulate areas (normalized with total cerebrum) were
categorized by type and the stage of dementia (Table
6). Average z-scores are defined as the loss of metabolic
activity in the posterior cortical regions (parietal, occipital,
and posterior cingulate). The average z-scores of the AD
patients were significantly higher than those of the FTD
patients (Figure 3). Conversely, no significant difference
was found between the AD and FTD groups with regards

PARIETAL
OCCIPITAL
POSTERIOR CINGULATE
TEMPORAL
FRONTAL
ANTERIOR CINGULATE

6

4

2

0
AD

FTD

Figure 1. The distribution of z-scores in the specific cortical regions in the AD
and FTD groups. Numbers near circles represent the number of the patient in
Table 2.
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Figure 2. Case no. 24: (A) Assessment of the neuropsychometric tests and clinical findings revealed a significant decrease in FDG uptake
in all anterior and posterior cortical regions [other than the primary motor and sensorial regions and visual cortexes (occipital cortical
regions)] in the axial FDG-PET brain images of a 68-year-old female patient with an early diagnosis of undefined advanced dementia.
(B) Obvious z-score deviations in accordance with the 55–91 year age range average were observed in 3D-SSP (NEUROSTAT) images
in the bilateral temporo-parietal-occipital, bilateral posterior, anterior cingulate, and bilateral frontal regions. This image resembles
advanced-stage Alzheimer disease. The patient was diagnosed with Alzheimer disease through consensus diagnosis.

FTD

AD

Table 5. The consistency of the z-scores derived from different normalizations.
Total cerebrum normalization & thalamus normalization

r = 0.858

Total cerebrum normalization & cerebellum normalization

r = 0.842

Total cerebrum normalization & pons normalization

r = 0.814

Total cerebrum normalization & thalamus normalization

r = 0.978

Total cerebrum normalization & cerebellum normalization

r = 0.930

Total cerebrum normalization & pons normalization

r = 0.941

to the scores of the frontal, anterior cingulate, and temporal
regions.
Cortical z-scores are evaluated throughout the stages
of dementia. In the early-stage AD group (although the
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patient number was low), pathological change (Z > 1.5)
was only observed in the posterior cingulate cortex.
The patients with moderate and advanced AD also had
pathological changes in z-scores for the parietal, temporal,

0.84 ± 0.42 0.72 ± 0.35 1.82 ± 1.62 1.96 ± 1.05 1.98 ± 1.17 2.16 ± 1.18 0.52 ± 0.47 0.55 ± 0.57 1.17 ± 0.33 1.3 ± 0.33

2.16 ± 0.9

1.53 ± 0.73 1.92 ± 0.73 2.36 ± 0.88 2.49 ± 0.94 2.17 ± 1.15 2.44 ± 0.95

<0.0001

<0.0001

0.166

0.224

AD = Alzheimer dementia, FTD = frontotemporal dementia, R = right, L = left.

AD & FTD (t-test P-value)

0.872

0.333

<0.0001

<0.0001

<0.0001

<0.0001

0.133

0.058

Sum of the FTD group (n = 20) (mean ± STD) 0.75 ± 0.38 0.74 ± 0.36 1.66 ± 1.33 1.85 ± 1.09 1.79 ± 1.36 2.02 ± 1.42 0.52 ± 0.53 0.64 ± 0.72 1.26 ± 0.37 1.35 ± 0.37 2.63 ± 1.68 2.85 ± 1.57

3.05 ± 1.61 3.22 ± 1.39

0.96 ± 0.44 1.99 ± 1.33 2.37 ± 1.16 1.29 ± 0.39 1.87 ± 1.01 0.45 ± 0.68 0.82 ± 1.02 1.12 ± 0.47 1.24 ± 0.48 2.55 ± 1.89 2.93 ± 1.81

2.03 ± 1.99 2.02 ± 1.97 0.59 ± 0.45 0.58 ± 0.47 1.46 ± 0.17 1.49 ± 0.23 2.28 ± 1.56 2.42 ± 1.49

1.83 ± 0.9

2.64 ± 0.69 1.96 ± 1.07 1.92 ± 0.92

Late-stage FTD (n = 7) (mean ± SD)

2.22 ± 0.98 2.66 ± 0.9

0.57 ± 0.17 1.22 ± 0.91 1.3 ± 0.8

3.2 ± 0.89

2.03 ± 1.15 1.58 ± 1.14 1.55 ± 0.68 1.71 ± 0.49 3 ± 0.87

0.62 ± 0.4

L

Moderate-stage FTD (n = 6) (mean ± SD)

R

0.78 ± 0.3

L

Early-stage FTD (n = 7) (mean ± SD)

R

2.63 ± 1.29 2.67 ± 1.18 2.04 ± 1.09 2.09 ± 0.99 1.81 ± 1.03 1.72 ± 1.06 1.35 ± 0.76 1.59 ± 0.76 2.47 ± 0.94 2.37 ± 0.86 2.05 ± 1.14 2.16 ± 1.02

L

Sum of the AD group (n = 28) (mean ± SD)

R

2.7 ± 0.97

L

Anterior cingulate

Late-stage AD (n = 13) (mean ± SD)

R

Posterior cingulate

0.89 ± 0.16 1.32 ± 0.76 1.06 ± 0.38 0.45 ± 0.27 0.42 ± 0.38 1.76 ± 0.31 1.65 ± 0.51 2.07 ± 1.43 2.13 ± 1.47

L

Occipital

3.26 ± 1.28 2.88 ± 1.08 2.13 ± 1.18 2.02 ± 0.8

1.48 ± 09

R

Frontal

Moderate-stage AD (n = 12) (mean ± SD)

L

Temporal

0.99 ± 0.69 0.9 ± 0.36

R

Parietal

Early-stage AD (n = 3) (mean ± SD)

Classification of consensus diagnosis

Table 6. The distribution of the regional cortical z-score averages according to the disease groups and stages.
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Figure 3. Case no. 30: (A) Assessment of the neuropsychometric tests and clinical findings revealed that there was a significant decrease
in FDG uptake in the bilateral frontal lobes, which also partially expanded to the temporal regions in the axial FDG-PET brain images
of a 54-year-old female patient whose type of dementia could not be defined and was therefore diagnosed with undefined advanced
dementia. This resembles frontotemporal dementia. Hypometabolism was observed in the same regions in accordance with the
(B) 31–55 year age range average in the 3D-SSP (NEUROSTAT) images. This was defined as frontotemporal dementia through
consensus diagnosis.

occipital, frontal, and anterior cingulate regions, as well.
In early-stage FTD patients, the z-scores of the temporal
region were relatively normal. In addition, the z-scores of
the frontal and anterior cingulate regions were affected
similarly in all stages of FTD.
When consensus diagnosis is considered as the
reference, the sensitivity, specificity, accuracy, and positive
and negative predictive values of PET scan for the diagnosis
of AD were 93%, 85%, 90%, 90%, and 89%, respectively.
On the other hand, the sensitivity, specificity, accuracy,
and positive and negative predictive values of PET scan for
the diagnosis of FTD were 85%, 93%, 90%, 89%, and 90%,
respectively.
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4. Discussion
In AD, neurodegeneration develops in the temporoparietal-occipital cortex and in the frontal lobes stemming
from the posterior cingulate cortex. FDG-PET scanning
shows a typical hypometabolic distribution pattern in
these affected regions. Several studies have reported that
PET scan is a useful method in both the diagnosis of AD
and in the differentiation of different types of dementia.
Silverman et al. reported that 91 of 97 AD patients
were accurately diagnosed with a PET scan (sensitivity:
94%), and this diagnosis was verified with postmortem
neuropathological examinations. On the other hand, in
those with non-AD dementia, the absence of AD was
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accurately depicted by PET in 30 of 41 patients (specificity:
73%). Additionally, that published study indicated that
the development of a cognitive deformity was very low
(negative probability rate: 0.10; 95% CI: 0.06–0.16) based
on a follow-up of on average 3 years in patients with
normal PET scans (10). Patwardhan et al. conducted a
metaanalysis of 15 studies that were published between
1989 and 2003 regarding the contribution of FDG-PET
in the diagnosis of AD. The heterogeneous distribution
of the sensitivity and specificity values was 86% (95% CI:
76%–93%) and 86% (95% CI: 72%–93%), respectively.
The heterogeneous distribution could not be explained,
which indicates that the sensitivity and specificity of FDGPET may be limited. A recently published summary of 5
studies, in which a new-generation PET scanner was used,
indicated that the accuracy, sensitivity, and specificity of
FDG-PET in the diagnosis of AD were 93%, 96%, and
90%, respectively (4).
In our study, the consensus diagnosis was considered
as the reference point, and the sensitivity, specificity,
accuracy, and positive and negative predictive values of
PET in the diagnosis of AD were 93%, 85%, 90%, 90%, and
89%, respectively. In addition, the sensitivity, specificity,
accuracy, and positive and negative predictive values of
PET in diagnosing FTD were 85%, 93%, 90%, 89%, and
90%, respectively. Since our results were obtained from
selected patient groups and were not based on a definitive
reference for diagnosis, there may be doubts regarding the
reliability of this study. However, that FDG-PET was able
to determine the type of dementia for 14 (29%) clinically
undiagnosed cases in agreement with the consensus
diagnosis indicates the usefulness of this method.
Jagust et al. reported that FDG-PET (sensitivity: 84%,
specificity: 74%) is better for diagnosing AD than a clinical
assessment in the early stages (sensitivity: 76%, specificity:
58%) (14). Similarly, Foster et al. stated that FDG-PET
(sensitivity: 96.7%, specificity: 85.7%) is superior to clinical
methods in the differential diagnosis of FTD and AD (15).
In the current study, the mean z-score values of AD
patients were significantly higher than those of the FTD
group in the posterior cortical regions (parietal, occipital,
and posterior cingulate). On the other hand, the mean
z-score values in the anterior cortical regions (frontal,
anterior cingulate, and anterior temporal) were higher
in patients with FTD, but no significant difference was
found between the AD and FTD patient groups. This is
an unexpected observation that may be explained by the
fact that the anterior cortex is affected in addition to the
posterior cortex regions, since most of the AD patients in
our study were considered to be in the middle/advanced

stages of the disease. Therefore, we observed a considerable
similarity of metabolic distribution patterns between the
AD and FTD patients in these regions, with the exclusion
of the parietal and occipital cortexes.
The assessment of 18F-FDG PET images requires
experience; the evaluator must be familiar with the normal
changes that are associated with aging in cerebral glucose
metabolism. It is very difficult to distinguish the posterior
cingulate gyrus activity by visual assessment, especially
when diagnosing early-stage AD. Furthermore, even
experienced physicians can have discordant results with
visual assessments (16). Statistical parametric mapping
software (SPM, NEUROSTAT, etc.) that is capable of
assessing the cerebral cortical counts with a normal
database on a voxel basis and performing quantitative
analysis has been developed in order to reduce these
inconsistencies (17). The variations between physicians
can be significantly decreased by using this software,
which is more objective in assessment (13). This software
can be efficiently used for assessing deep and small cortical
regions, such as the posterior cingulate gyrus, which is
difficult to evaluate by visual assessment (18).
Minoshima et al. explained how the 3D-SSP program
can be used for evaluating FDG-PET brain images for
diagnosing AD (13). This program was also used in our
study for analyzing the images, in addition to visual
assessment. To our knowledge, we are the first to use
this program in Turkey. Since the program’s database
is originally from North America, a national database
integrated to the program is required for Turkey. However,
it should be kept in mind that this type of software can
be affected by patient movement, by faulty positioning
of the patient during imaging, or by an already existing
structural deformity within the brain. Ultimately, these
types of automatic analysis programs should be used, but
only when backed up by visual assessment and clinical
information.
In conclusion, FDG-PET imaging can be a
beneficial method for the evaluation of dementia
diseases, especially in cases where the clinical findings
are nondifferentiating, the type of dementia cannot be
defined with neuropsychological tests, or the physician is
not certain about the diagnosis. This study had a limited
number of patients, but we found that the diagnostic
accuracy of FDG-PET scanning was significant for the
clinical diagnosis of both AD and FTD. Furthermore,
using 3D software in addition to the visual assessment
of brain FDG-PET images can increase the diagnostic
accuracy and decrease the variability in the interpretations
by different physicians/centers.
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